It helps regulate blood sugar by stimulating insulin, suppressing glucagon and slowing digestion
Many doctors anticipate that the medication may be FDA approved sometime in 2027, Siegel says
As I mentioned, some people may also experience mild digestive discomfort, especially when first starting supplementation
It is FDA-indicated for three main uses: Cardiovascular Risk Reduction (In a Specific Group) To reduce the risk of major adverse cardiovascular events such as cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with established cardiovascular disease who also have obesity or are overweight
The GCGR arm adds hepatic thermogenesis and lipolysis that tirzepatide does not generate
All pricing includes the initial online doctor consult, the medication vial, syringes and alcohol pads, and free overnight shipping to your door